Peregrine Asset Advisers’s CytomX Therapeutics CTMX Stock Holding History

Peregrine Asset Advisers’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$38.3K	Hold	10,200	–	–	0.01%	217
2026 Q1	$47.9K	Buy	10,200 +200	+2%	+$1.01K	0.01%	189
2025 Q4	$42.6K	Hold	10,000	–	–	0.01%	175
2025 Q3	$31.9K	Hold	10,000	–	–	0.01%	176
2025 Q2	$22.7K	Hold	10,000	–	–	0.01%	168
2025 Q1	$6.36K	Hold	10,000	–	–	﹤0.01%	161
2024 Q4	$10.3K	Hold	10,000	–	–	﹤0.01%	167
2024 Q3	$11.8K	Buy	+10,000	New	+$12.7K	﹤0.01%	181

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Peregrine Asset Advisers's CTMX Position: Q2 2026 in Review

Peregrine Asset Advisers held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 10,200 shares worth $38.3K. The position accounts for 0.01% of the portfolio, ranked #217.

Peregrine Asset Advisers first reported a position in CTMX in Q3 2024 and has held it in 8 quarters since. The position peaked at $47.9K in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Peregrine Asset Advisers held 10,200 shares of CytomX Therapeutics worth $38.3K as of Q2 2026.
Peregrine Asset Advisers left its CytomX Therapeutics share count unchanged in Q2 2026.
CytomX Therapeutics made up 0.01% of Peregrine Asset Advisers's portfolio in Q2 2026, its #217 holding.
Peregrine Asset Advisers first reported a position in CytomX Therapeutics in Q3 2024 and has held it in 8 quarters since.
Peregrine Asset Advisers's CytomX Therapeutics position peaked at $47.9K in Q1 2026.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Peregrine Asset Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.